Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05382273 · ClinicalTrials.gov registry record
Cannabis Tolerance Break Resource Study: T-Break Guide
A clinical trial of Cannabis Use and Tolerance, sponsored by University of Vermont.
- Completed
- Registry status
- 151
- Enrollment target
- 1
- Study location
NCT05382273: Completed study of Cannabis Use and Tolerance, sponsored by University of Vermont.
NCT05382273 is a study of Cannabis Use and Tolerance that has completed, run by University of Vermont. The registered enrollment target is 151 participants, below the 276-participant average among 44 other Cannabis Use trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05382273, a study of Cannabis Use and Tolerance, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- 151 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this pilot study is to conduct research into the value of using the T-Break Guide for assisting people taking a tolerance break from cannabis. The hope is that this initial research will yield some insights and benchmarks into the Guide's efficacy, and provide a foundation for a later randomized control study. The following are some key research questions: 1. How did participants use the Guide? (Eg: daily; read once; 'a la carte') 2. How did using the Guide increase fidelity to tolerance break (starting, continuing, completing a break)? 3. Did using the Guide yield any benefits beyond tolerance break fidelity? (Eg: insight into patterns of use)
Primary Outcome
Did the participant go 21 days without using cannabis? Self-report, "yes/no" question on followup survey
Conditions Studied
Interventions
- BEHAVIORAL T-Break Guide
Study Locations (1)
Vermont
- University of Vermont - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2021-04-22 |
| Est. Completion | 2021-08-01 |
What the finished NCT05382273 record still lists
NCT05382273 is an observational study that tracks outcomes without assigning an intervention. The registered 151 participants enrollment target is mid-sized for trials with a published cap, below the 276-participant average among 44 other Cannabis Use trials with a reported enrollment target (45% lower).
The record links to 3 conditions, with Cannabis Use appearing as the primary indexed condition, and to 1 intervention - of which T-Break Guide is the first listed.
NCT05382273 reports a single indexed study location in Vermont.
Frequently Asked Questions
What is clinical trial NCT05382273 about?
NCT05382273 is a clinical study titled "Cannabis Tolerance Break Resource Study: T-Break Guide". The purpose of this pilot study is to conduct research into the value of using the T-Break Guide for assisting people taking a tolerance break from cannabis. The hope is that this initial research will yield some insights and benchmarks into the Guide's efficacy, and provide a foundation for a later...
What is the current status of trial NCT05382273?
This trial is currently completed. The enrollment target is 151 participants. The study started on 2021-04-22. Estimated completion is 2021-08-01.
What conditions does trial NCT05382273 study?
This clinical trial studies the following conditions: Cannabis Use, Tolerance, Cannabis Withdrawal.
What interventions are being tested in trial NCT05382273?
The interventions under investigation include: T-Break Guide (BEHAVIORAL).
Who is sponsoring clinical trial NCT05382273?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05382273 being conducted?
This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis Use
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05382273's enrollment target sits among peer trials
151 15th of 44 higher than 30 of 44 other Cannabis Use trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cannabis Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility/Acceptability of a Brief Motivational Intervention for Frequent/High-Intensity Cannabis Use
RECRUITING · NA
-
Effect of Cannabis on Cigarette Use Behavior
RECRUITING · Phase 1
-
SV2A in Older Adults
RECRUITING · Phase 1
-
Cannabis' Impact on Alcohol Consumption
RECRUITING · Phase 2
-
Distinguishing Alcohol Intoxication, Cannabis Intoxication and Co-intoxication Using Electroencephalography (EEG)
RECRUITING · NA
-
HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01409161 · 151 participants · Phase 2
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- NCT04245397 · 151 participants · Phase 1
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
- NCT05761223 · 151 participants · Phase 1
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
- NCT07195656 · 151 participants · NA
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI